Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Withania somnifera (WSE; Ashwagandha in Ayurveda) extracts have been used as an adaptogen or to build resistance to stress or diseases in indigenous medical systems in India for centuries. Modern scientific data for WSE indicate several bioactive molecules (withanolides, withanosides, indosides, withaferin-A, others) with significant immunomodulatory, anti-inflammatory and stress reducing properties.
This study will examine whether a standardized extract of Withania Somnifera (WSE; Sensoril®) will improve total, positive, negative symptoms, and stress in patients with schizophrenia. The study will examine whether WSE reduces PANSS positive and negative symptoms and stress scores in subjects, and whether these improvements are mediated by changes in inflammatory immune indices. An additional aim will determine if patients receiving WSE will have fewer adjustments to their psychotropic medications that those assigned to placebo. The study will examine whether WSE will re-balance Th1/Th2 ratios (cytokine measures) and mediate a reduction of elevated hs-CRP levels. It is hypothesized that those subjects whose Th1/Th2 ratios normalize will likely have a greater magnitude of clinical improvement versus those subjects whose immune ratios remain unbalanced.
The proposal is a 12-week, double-blind, placebo-controlled RCT of WSE added to antipsychotic medications in approximately 60 or more patients with schizophrenia with an exacerbation of symptoms. If efficacy is affirmed, this low cost extract could be studied further, and used quite readily across low, middle and high income countries.
The primary aim is to determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total) and stress scores(PSS total) in persons with schizophrenia?
The study will also determine whether WSE reduces measures of positive and negative and general symptoms of schizophrenia (PANSS subscale scores)?
Another primary aim will be to determine if changes in antipsychotic and/or other psychotropic medications (lithium, anticonvulsants, antidepressants, anxiolytic agents or hypnotics) (examples: dosage escalation or reductions or switch or stoppage) will favor the group receiving the standardized Withania somnifera extract versus those receiving placebo. Even though we expect changes in antipsychotic medications to occur when patients experience an exacerbation of psychotic symptoms (or other psychiatric symptoms), we hypothesize that those receiving the standardized Withania somnifera extract will experience fewer medication adjustments then those assigned to placebo.
A secondary aim is to determine whether WSE will rebalance TH1/TH2 ratios (cytokine measures) and mediate a reduction of elevated hs-CRP levels? The study will assess whether those subjects whose TH1/TH2 ratios normalize have a greater magnitude of clinical improvement vs. those subjects whose immune ratios remain unbalanced. Similarly, the study will assess whether reduction of hsCRP levels correlate with improvements in PANSS total and subscale scores or the PSS total scores.
Eighty or more patients with DSM IV TR (or if instituted by the study initiation: DSM V) schizophrenia or schizoaffective disorder will be screened and 60 or more eligible patients will be enrolled in a 12 week placebo controlled double blind study. Subjects who have experienced an exacerbation of positive symptoms (delusions, hallucinations, etc). Subjects receiving medications that affect the immune-inflammatory system will be excluded and those receiving antibiotics, antiviral or anti-parasitic medications will be excluded.
Base line laboratory and EKG examination will be carried out to establish eligibility for study participation. In addition specific laboratory analyses of immune markers namely interleukin-2, interferon gamma, interleukin-4, interleukin 6 and high sensitivity C-Reactive Protein will be carried out.
Sixty or more patients will be randomly assigned to receive either WSE or matching placebo starting with 1 capsule of 250 mg strength twice a day (total daily dose = 500 mg) for the first week which will be increased to 2 capsules of 250 mg twice daily (total daily dose = 1000 mg) for a total treatment period of 12 weeks. An assessment of psychopathology (PANSS) and stress will be carried out at each scheduled visit. Assessments of safety including vital signs and treatment emergent adverse events will also be carried out at each visit. Immune-inflammatory markers will be re-assessed at the final visit.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sensoril® | Experimental | Sensoril® is a proprietary extract of Withania Somnifera |
|
| Placebo | Placebo Comparator | Placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sensoril® | Drug | Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera |
|
| Measure | Description | Time Frame |
|---|---|---|
| Positive and Negative Syndrome Scale (PANSS) | The Positive and Negative Syndrome Scale (PANSS) measures symptom severity in patients with psychotic illnesses. It yields a total score as well as subscores for Positive symptoms, Negative symptoms and General symptoms. PANSS Positive subscale consists of 7 Items - (minimum score = 7, maximum score = 49) - Higher values represent a worse outcome. PANSS Negative subscale consists of 7 Items - (minimum score = 7, maximum score = 49) - Higher values represent a worse outcome. General Psychopathology subscale consists of 16 items - (minimum score = 16, maximum score = 112) - Higher values represent a worse outcome. PANSS Total Score - The 3 subscales scores are summed to compute a PANSS Total score. The minimum PANSS total score = 30, maximum = 210 - Higher values represent a worse outcome | Baseline and 12 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Perceived Stress Scale (PSS) | The Perceived Stress Scale (PSS) was developed to measure the degree to which situations in one's life are appraised as stressful. Perceived Stress Scale Scoring Each item is rated on a 5-point scale ranging from never (0) to very often (4). Positively worded items are reverse scored, and the ratings are summed, with higher scores indicating more perceived stress. PSS-10 scores are obtained by reversing the scores on the four positive items: For example, 0=4, 1=3, 2=2, etc. and then summing across all 10 items. Items 4, 5, 7, and 8 are the positively stated items. Total score can range from 0 to 40. Scores around 13 are considered average. Scores of 20 or higher are considered high stress, |
| Measure | Description | Time Frame |
|---|---|---|
| Vital Signs - Weight | Clinically significant changes in weight will be assessed for "normal" or "abnormal" following randomization to 12 weeks or end of study | Baseline and 12 weeks or end of study |
| Vital Signs - Body Mass Index |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| KN Roy Chengappa, MD | University of Pittsburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Western Psychiatric Institute & Clinic | Pittsburgh | Pennsylvania | 15213 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29995356 | Derived | Chengappa KNR, Brar JS, Gannon JM, Schlicht PJ. Adjunctive Use of a Standardized Extract of Withania somnifera (Ashwagandha) to Treat Symptom Exacerbation in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2018 Jul 10;79(5):17m11826. doi: 10.4088/JCP.17m11826. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Sensoril® | Sensoril® is a proprietary extract of Withania Somnifera Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera |
| FG001 | Placebo | Placebo Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
34 subjects were randomized in each group but 1 subject in each group never came to pick up study medication and therefore are not included in the Overall number of participants analyzed in each outcome measure. They did not contribute any data to the intention to treat group.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Sensoril® | Sensoril® is a proprietary extract of Withania Somnifera Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera |
| BG001 | Placebo |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Positive and Negative Syndrome Scale (PANSS) | The Positive and Negative Syndrome Scale (PANSS) measures symptom severity in patients with psychotic illnesses. It yields a total score as well as subscores for Positive symptoms, Negative symptoms and General symptoms. PANSS Positive subscale consists of 7 Items - (minimum score = 7, maximum score = 49) - Higher values represent a worse outcome. PANSS Negative subscale consists of 7 Items - (minimum score = 7, maximum score = 49) - Higher values represent a worse outcome. General Psychopathology subscale consists of 16 items - (minimum score = 16, maximum score = 112) - Higher values represent a worse outcome. PANSS Total Score - The 3 subscales scores are summed to compute a PANSS Total score. The minimum PANSS total score = 30, maximum = 210 - Higher values represent a worse outcome | 34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes | Posted | Mean | Standard Deviation | units on a scale | Baseline and 12 Weeks |
|
Adverse Events were evaluated during the study period (12 weeks)
34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Sensoril® | Sensoril® is a proprietary extract of Withania Somnifera Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| loose stools/diarrhea | Gastrointestinal disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. K.N. Roy Chengappa - PI | University of Pittsburgh | 412-246-5006 | chengappakn@upmc.edu |
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| D011618 | Psychotic Disorders |
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C030693 | Ashwagandha |
| D000073893 | Sugars |
| ID | Term |
|---|---|
| D002241 | Carbohydrates |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules. |
|
|
| Baseline and 12 weeks or end of treatment |
| Clinical Global Impression Scale (CGI-S) - Severity | The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are: 0 = not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill patients - The higher the score the worse outcome | Baseline and 12 weeks or end of study |
| Number of Participants With a Score of 1, 2, or 3 on the Clinical Global Impression Improvement Scale | The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: Possible ratings are: 1= Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5= Minimally worse, 6= Much worse, 7=Very much worse. The higher the score the worse outcome | 12 weeks |
| Immune Marker IL-2 | Changes in immune marker IL-2 will be assessed in response to study medication. | Baseline and 12 weeks or end of study |
| Immune Marker IL-4 | Changes in immune marker IL-4 will be assessed in response to study medication. | Baseline and12 weeks or end of study |
| Immune Marker IL-6 | Changes in immune marker IL-6 will be assessed in response to study medication. | Changes from Baseline in Immune markers at 12 weeks or end of study |
| Immune Marker IFN-Y (Gamma) | Changes in immune marker IFN-Y (gamma) will be assessed in response to study medication. | Baseline and 12 weeks or end of study |
| Immune Marker Hs-CRP (High Sensitivity C Reactive Protein) | Changes in immune marker hs-CRP (high sensitivity C Reactive Protein) will be assessed in response to study medication. hsCRP - mg/L | Baseline and 12 weeks or end of study |
| Immune Marker S-100B | Changes in immune marker S-100B will be assessed in response to study medication. Elisa
| Baseline and 12 weeks or end of treatment |
Clinically significant changes in BMI will be assessed for "normal" or "abnormal" following randomization to 12 weeks or end of study.
| Baseline and 12 weeks or end of study |
| Vital Signs - Blood Pressure Systolic and Diastolic | Clinically significant changes in BP will be assessed for "normal" or "abnormal" following randomization to 12 weeks or end of study. | Baseline and 12 weeks or end of study |
| Vital Signs - Pulse | Clinically significant changes in Pulse will be assessed for "normal" or "abnormal" following randomization to 12 weeks or end of study. | Baseline and 12 weeks or end of study |
| Vital Signs - Temperature | Clinically significant changes in Temperature will be assessed for "normal" or "abnormal" following randomization to 12 weeks or end of study. | Baseline and 12 weeks or end of study |
| Laboratory Analytes | Changes in laboratory analytes will be classified as "normal" or "abnormal" (example: white blood cell counts) | Change from Baseline in Laboratory Analytes at 12 weeks or end of study |
| Adverse Event |
|
| Patient did not take study medication |
|
| Lost to Follow-up |
|
Placebo Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules. |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| Diagnosis Schizophrenia or Schizoaffective | Count of Participants | Participants |
|
| Number of lifetime psychiatric hospitalizations | Mean | Standard Deviation | psychiatric hospitalizations |
|
| Age at onset of 1st episode | Mean | Standard Deviation | years |
|
| Current Smokers | Count of Participants | Participants |
|
| Description |
|---|
| OG000 | Sensoril® | Sensoril® is a proprietary extract of Withania Somnifera Sensoril®: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera |
| OG001 | Placebo | Placebo Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules. |
|
|
| Secondary | Perceived Stress Scale (PSS) | The Perceived Stress Scale (PSS) was developed to measure the degree to which situations in one's life are appraised as stressful. Perceived Stress Scale Scoring Each item is rated on a 5-point scale ranging from never (0) to very often (4). Positively worded items are reverse scored, and the ratings are summed, with higher scores indicating more perceived stress. PSS-10 scores are obtained by reversing the scores on the four positive items: For example, 0=4, 1=3, 2=2, etc. and then summing across all 10 items. Items 4, 5, 7, and 8 are the positively stated items. Total score can range from 0 to 40. Scores around 13 are considered average. Scores of 20 or higher are considered high stress, | 34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes | Posted | Mean | Standard Deviation | units on a scale | Baseline and 12 weeks or end of treatment |
|
|
|
| Secondary | Clinical Global Impression Scale (CGI-S) - Severity | The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Possible ratings are: 0 = not assessed, 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 = Moderately ill, 5 = Markedly ill, 6 = Severely ill, 7 = Among the most extremely ill patients - The higher the score the worse outcome | 34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes | Posted | Mean | Standard Deviation | units on a scale | Baseline and 12 weeks or end of study |
|
|
|
| Secondary | Number of Participants With a Score of 1, 2, or 3 on the Clinical Global Impression Improvement Scale | The Clinical Global Impression - Improvement scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. and rated as: Possible ratings are: 1= Very much improved, 2=Much improved, 3=Minimally improved, 4=No change, 5= Minimally worse, 6= Much worse, 7=Very much worse. The higher the score the worse outcome | 34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes | Posted | Count of Participants | Participants | 12 weeks |
|
|
|
| Secondary | Immune Marker IL-2 | Changes in immune marker IL-2 will be assessed in response to study medication. | IL-2 levels undetectable. | Posted | Mean | Standard Deviation | pg/mL | Baseline and 12 weeks or end of study |
|
|
|
| Secondary | Immune Marker IL-4 | Changes in immune marker IL-4 will be assessed in response to study medication. | Data cannot be summarized- IL-4 levels undetectable | Posted | Mean | Standard Deviation | pg/mL | Baseline and12 weeks or end of study |
|
|
|
| Secondary | Immune Marker IL-6 | Changes in immune marker IL-6 will be assessed in response to study medication. | The "number analyzed" differs from the "overall number of participants analyzed" because not all participants had baseline and end of treatment values for IL-6. | Posted | Mean | Standard Deviation | pg/mL | Changes from Baseline in Immune markers at 12 weeks or end of study |
|
|
|
| Secondary | Immune Marker IFN-Y (Gamma) | Changes in immune marker IFN-Y (gamma) will be assessed in response to study medication. | data cannot be summarized IFN-Y (gamma) levels undetectable | Posted | Mean | Standard Deviation | pg/mL | Baseline and 12 weeks or end of study |
|
|
|
| Secondary | Immune Marker Hs-CRP (High Sensitivity C Reactive Protein) | Changes in immune marker hs-CRP (high sensitivity C Reactive Protein) will be assessed in response to study medication. hsCRP - mg/L | The "number analyzed" differs from the "overall number of participants analyzed" because not all participants had baseline and end of treatment values for hs-CRP. | Posted | Mean | Standard Deviation | mg/L | Baseline and 12 weeks or end of study |
|
|
|
| Secondary | Immune Marker S-100B | Changes in immune marker S-100B will be assessed in response to study medication. Elisa
| The "number analyzed" differs from the "overall number of participants analyzed" because not all participants had baseline and end of treatment values for S-100B. | Posted | Mean | Standard Deviation | pg/mL | Baseline and 12 weeks or end of treatment |
|
|
|
| Other Pre-specified | Vital Signs - Weight | Clinically significant changes in weight will be assessed for "normal" or "abnormal" following randomization to 12 weeks or end of study | 34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes | Posted | Mean | Standard Deviation | lbs | Baseline and 12 weeks or end of study |
|
|
|
| Other Pre-specified | Vital Signs - Body Mass Index | Clinically significant changes in BMI will be assessed for "normal" or "abnormal" following randomization to 12 weeks or end of study. | 34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes | Posted | Mean | Standard Deviation | kg/m^2 | Baseline and 12 weeks or end of study |
|
|
|
| Other Pre-specified | Vital Signs - Blood Pressure Systolic and Diastolic | Clinically significant changes in BP will be assessed for "normal" or "abnormal" following randomization to 12 weeks or end of study. | 34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes | Posted | Mean | Standard Deviation | mm/Hg | Baseline and 12 weeks or end of study |
|
|
|
| Other Pre-specified | Vital Signs - Pulse | Clinically significant changes in Pulse will be assessed for "normal" or "abnormal" following randomization to 12 weeks or end of study. | 34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes | Posted | Mean | Standard Deviation | beats/min | Baseline and 12 weeks or end of study |
|
|
|
| Other Pre-specified | Vital Signs - Temperature | Clinically significant changes in Temperature will be assessed for "normal" or "abnormal" following randomization to 12 weeks or end of study. | 34 subjects were randomized to each treatment group, but 1 subject in each group did not return to pick up study medication and therefore were not included in the Intention-to-Treat (ITT) sample for analysis of outcomes | Posted | Mean | Standard Deviation | degrees F | Baseline and 12 weeks or end of study |
|
|
|
| Other Pre-specified | Laboratory Analytes | Changes in laboratory analytes will be classified as "normal" or "abnormal" (example: white blood cell counts) | Not Posted | Change from Baseline in Laboratory Analytes at 12 weeks or end of study | Participants |
| 0 |
| 33 |
| 0 |
| 33 |
| 24 |
| 33 |
| EG001 | Placebo | Placebo Placebo: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules. | 0 | 33 | 0 | 33 | 20 | 33 |
| dry mouth | Gastrointestinal disorders | Systematic Assessment |
|
| nausea | Gastrointestinal disorders | Systematic Assessment |
|
| dyspepsia (heartburn) | Gastrointestinal disorders | Systematic Assessment |
|
| epigastric discomfort | Gastrointestinal disorders | Systematic Assessment |
|
| anxiety | Psychiatric disorders | Systematic Assessment |
|
| hyperactive | Psychiatric disorders | Systematic Assessment |
|
| confusion | Psychiatric disorders | Systematic Assessment |
|
| worsening of psychiatric symptoms | Psychiatric disorders | Systematic Assessment |
|
| somnolence | Nervous system disorders | Systematic Assessment |
|
| headache | Nervous system disorders | Systematic Assessment |
|
| fatigue/lathargy | General disorders | Systematic Assessment |
|
| rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| weight gain | Metabolism and nutrition disorders | Systematic Assessment |
|
Not provided
Not provided
Not provided
| IL 6 level at end of treatment |
|
|
| End of Rx |
|
|
| S100B end of Rx |
|
|
| Diastolic BP at baseline |
|
| Diastolic BP at end of treatment |
|